[Federal Register Volume 83, Number 122 (Monday, June 25, 2018)]
[Notices]
[Pages 29562-29563]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13486]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Mutant IDH1
Inhibitors Useful for Treating Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: National Center for Advancing Translational Sciences, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive patent
license to practice the inventions embodied in the Patent Applications
listed in the Summary Information section of this notice to Apexx
Oncology, Inc., located in New York, NY.
DATES: Only written comments and/or applications for a license which
are received by the National Center for Advancing Translational
Sciences on or before July 10, 2018 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting
Manager, National Center for Advancing Translational Sciences, NIH,
9800 Medical Center Drive, Rockville, MD 20850, Phone: 301-217-9197,
Fax: 301-217-5736, or email [email protected]. A signed Confidential
Disclosure Agreement may be required to receive copies of the patent
applications.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. International Application No. PCT/US15/067406 filed on 12/22/
2015 which is entitled ``Mutant IDH1 Inhibitors Useful for Treating
Cancer'' (HHS Ref. No: E-243-2014/0-PCT-02), and
2. U.S. Provisional Application No. 62/353298 filed on 06/22/2016
which is entitled ``Mutant IDH1 Inhibitors Useful for Treating Cancer''
(HHS Ref. No. E-189-2016/0-US-01).
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America
and the University of North Carolina at Chapel Hill.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of Licensed Patent Rights
for the following: ``Therapeutics for cancers in humans which result
from or characterized by the presence of mutant IDH1.''
The inventions relate to a series of novel compounds that potently
and selectively inhibit mIDH1. These compounds reduce 2-HG levels in
cell lines in vitro as well as in human cancer cells grown in mouse
xenografts in vivo. These compounds show greater than 250-fold
selectivity for the mutant enzyme over the wild-type, show favorable in
vitro stability (in mouse, rat, dog and human hepatocyte exposure
studies), are AMES negative, and exhibit no significant metabolic CYP
liabilities. These compounds possess very favorable in vivo rodent
pharmacokinetics and bioavailability and are well tolerated in rodents,
even when dosed at high levels.
Thus, the compounds of the subject inventions can be used
individually or in combination to develop new therapies to treat
diseases which result from mutant IDH1 activity. The diseases caused by
mutant IDH1 activity include cancer (e.g., acute myeloid leukemia,
glioma, cholangiocarcinoma and potentially other solid tumors) and
selected rare diseases, such as Ollier Disease.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless
[[Page 29563]]
within fifteen (15) days from the date of this published notice, the
National Center for Advancing Translational Sciences receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Patent License Agreement.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: June 11, 2018.
Christopher P. Austin,
Director, Office of the Director, National Center for Advancing
Translational Sciences.
[FR Doc. 2018-13486 Filed 6-22-18; 8:45 am]
BILLING CODE 4140-01-P